ATHEM trial: what clinicians have said so far
Adjuvant Targeted-therapy for Patients With Resected High-risk EGFR-mutant Stage IB-IIA Non-small Cell Lung Carcinoma
- NCT05165355 ↗
- Unknown
- Tongji University
- Focused size, estimated: 1–150 verified statements once built
We haven't built an HCP commentary report on ATHEM (furmonertinib in resected EGFR-mutant stage IB-IIA non-small cell lung carcinoma) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on ATHEM so far
Podcasts, YouTube videos and posts on X and Bluesky we have indexed that name the trial. LinkedIn posts are read for reports and the Enterprise MCP, not yet for this index. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Indexed so far | |
|---|---|
| 4 posts on X, typically up to 18 once built |
The trial
ClinicalTrials.gov- Official title
- A Phase II, Single-armed Study to Assess the Efficacy and Safety of Furmonertinib in Patients With Epidermal Growth Factor Receptor Mutation Positive Stage IB-IIA Non-small Cell Lung Carcinoma, Following Complete Tumour Resection.
- Phase
- Phase 2
- Status
- Unknown
- Conditions
- NSCLC; EGF-R Positive Non-Small Cell Lung Cancer
- Interventions
- Furmonertinib
- Arms
- Experimental group · Experimental
- Enrollment
- 90 (estimated)
- Primary outcomes
- Disease Free Survival (DFS) rate at 2 years
- Sponsor
- Tongji University
- Start
- Dec 28, 2021
- Primary completion
- Nov 2024 (estimated)
- Results posted
- No
- Registry record
- NCT05165355 · updated Jan 18, 2022